# UC-050: Autonomous Adverse Event Report Processing in Pharmacovigilance

## Metadata

| Field            | Value                        |
|------------------|------------------------------|
| **ID**           | UC-050                       |
| **Category**     | Industry-Specific            |
| **Industry**     | Pharmaceutical / Life Sciences |
| **Complexity**   | High                         |
| **Status**       | `detailed`                   |

---

## Problem Statement

Pharmaceutical companies are legally required to collect, assess, and submit Individual Case Safety Reports (ICSRs) for every adverse drug reaction reported against their products. The FDA's FAERS database alone contains over 31 million report entries, with approximately 700,000 new adverse event reports filed annually in the US. The EMA's EudraVigilance system holds 29.3+ million ICSRs across 16.9 million unique cases in Europe.

Each ICSR requires a trained pharmacovigilance specialist to manually extract data from unstructured sources (physician narratives, patient emails, clinical trial case report forms, published literature), code medical terms to MedDRA dictionaries, assess causality, write a clinical narrative, and submit the case electronically in ICH E2B(R3) format — all within strict regulatory deadlines (7 days for fatal/life-threatening events, 15 days for other serious events).

A single routine case takes 2–4 hours of specialist time from intake through submission. Large pharma companies employ thousands of full-time pharmacovigilance staff globally, with per-product safety data management averaging $686K/year. Despite this investment, the manual process is error-prone and struggles to scale with growing report volumes driven by expanded drug portfolios, post-marketing surveillance requirements, and increasing patient self-reporting.

---

## Business Impact

| Dimension       | Description                               |
|-----------------|-------------------------------------------|
| **Cost**        | Per-product PV data management averages ~$686K/year. ICSR processing staff cost $38–$163/hr (median $44.20/hr). A mid-size CRO like ProPharma processes 2,000+ ICSRs/month — representing millions in annual labor cost. |
| **Time**        | 2–4 hours per routine ICSR (intake through submission). Serious/fatal cases require 7-day turnaround; other serious events require 15-day submission. Triage alone needs 24-hour turnaround. |
| **Error Rate**  | Manual MedDRA coding errors, missed duplicate reports, inconsistent causality assessments, and narrative quality issues are common. Regulatory inspections routinely flag data quality findings. |
| **Scale**       | ~700,000 AE reports/year in US alone (FDA FAERS). Large pharma companies handle tens of thousands of cases internally. Volume grows 10–15% annually with expanded portfolios and patient self-reporting. |
| **Risk**        | Late or inaccurate submissions trigger regulatory action — FDA warning letters, EMA non-compliance findings, potential market withdrawal. Missed safety signals can lead to patient harm and billion-dollar liability. |

---

## Current Process (Before AI)

1. **Intake**: AE reports arrive via multiple channels — HCP phone calls, patient emails, clinical trial sites, published literature, social media monitoring, partner companies. Staff manually open and categorize each incoming report.
2. **Triage**: A PV specialist reviews the report within 24 hours to determine if it meets the four minimum ICSR criteria (identifiable patient, identifiable reporter, at least one suspect drug, at least one adverse event) and classifies seriousness.
3. **Data Entry**: The specialist manually enters structured data into the safety database (Oracle Argus Safety, Veeva Vault Safety, or ArisGlobal LifeSphere) — patient demographics, drug details, event description, reporter information.
4. **Medical Coding**: Medical terms from the narrative are coded to MedDRA (Medical Dictionary for Regulatory Activities) preferred terms and lowest-level terms. Drug names are coded to the WHO Drug Dictionary.
5. **Duplicate Detection**: The specialist manually searches the database for potential duplicate reports based on patient identifiers, event dates, and reporter information.
6. **Causality Assessment**: A medical reviewer (often a physician or PharmD) evaluates whether the adverse event is related to the suspect drug, using WHO-UMC or Naranjo algorithms.
7. **Narrative Writing**: A clinical narrative summarizing the case is written in English, following company SOPs and regulatory expectations.
8. **Quality Review**: A second specialist reviews the completed case for accuracy, completeness, and consistency.
9. **Submission**: The case is exported in ICH E2B(R3) XML format and transmitted electronically to the relevant regulatory authorities (FDA via FAERS, EMA via EudraVigilance, national competent authorities).
10. **Follow-up**: Incomplete cases are tracked, and follow-up requests are sent to reporters for missing information.

### Bottlenecks & Pain Points

- **Unstructured intake**: Reports arrive as free-text emails, scanned PDFs, handwritten forms, and phone transcripts — requiring manual reading and interpretation before any structured data entry.
- **MedDRA coding inconsistency**: Different specialists code the same medical term differently, leading to inconsistent safety signal detection downstream.
- **Duplicate detection failures**: Manual search across millions of existing cases is unreliable — duplicates inflate signal detection statistics while missed duplicates waste processing effort.
- **Translation bottleneck**: Reports arrive in 30+ languages. Manual medical translation averages ~5 hours per case (TransPerfect Life Sciences reports reducing this to <1 minute with AI).
- **Peak volume surges**: Product launches, safety label changes, and media attention cause report volume spikes that overwhelm fixed-capacity teams, risking regulatory deadline breaches.
- **Chronic staffing pressure**: Experienced PV specialists take 12–18 months to train. High turnover in CRO environments compounds the staffing challenge.

---

## Desired Outcome (After AI)

An agentic AI system that autonomously handles the end-to-end ICSR processing pipeline — from intake through submission-ready case — with human-in-the-loop oversight for serious cases and causality assessment. The system should process routine, non-serious cases with minimal human intervention ("touchless" processing) while flagging complex, serious, or ambiguous cases for expert review.

### Success Criteria

| Metric                   | Target                                  |
|--------------------------|-----------------------------------------|
| Processing time per case | < 30 minutes for routine cases (from 2–4 hours) |
| Manual effort reduction  | 50–65% reduction in specialist FTE hours |
| Data accuracy at intake  | > 90% field-level accuracy (ArisGlobal NavaX benchmark) |
| Regulatory compliance    | 100% on-time submission rate within 7/15-day deadlines |
| Touchless processing     | 40–60% of non-serious cases processed without human intervention |
| Signal detection improvement | 20% improvement in signal detection accuracy (Tech Mahindra benchmark) |
| Case prioritization      | 45% improvement in triage prioritization accuracy |

---

## Stakeholders

| Role                         | Interest                                    |
|------------------------------|---------------------------------------------|
| VP Drug Safety / QPPV        | Regulatory compliance, on-time submissions, liability reduction |
| PV Operations Manager        | Reduce manual workload, handle volume spikes, lower overtime costs |
| Medical Safety Officer       | Accurate causality assessment, reliable signal detection |
| IT / Platform Engineering    | System integration, data security, validation (GxP/CSV) |
| Regulatory Affairs           | ICH E2B(R3) compliance, inspection readiness |
| Quality Assurance            | Audit trails, SOPs, change control for AI systems |
| Chief Financial Officer      | Reduce per-product PV cost, avoid regulatory fines |

---

## Constraints

| Constraint              | Detail                          |
|-------------------------|---------------------------------|
| **Data Privacy**        | Patient PII and protected health information (PHI) in every report. GDPR (EU), HIPAA-adjacent sensitivity (US), and country-specific data residency requirements. All processing must occur within validated, access-controlled environments. |
| **Latency**             | Near-real-time for triage (24-hour regulatory clock starts at awareness). Batch acceptable for literature screening. Submission deadlines are hard regulatory requirements (7/15/90 days). |
| **Budget**              | Must demonstrate ROI within 12–18 months. Cloud compute costs for LLM inference at scale (tens of thousands of cases/month) must stay below current FTE cost savings. |
| **Existing Systems**    | Must integrate with incumbent safety databases — Oracle Argus Safety, Veeva Vault Safety, or ArisGlobal LifeSphere. Cannot replace the safety database; must augment it. |
| **Compliance**          | GxP / Computer System Validation (CSV) requirements for any system touching regulatory submissions. Emerging 2026 inspection guidance for AI validation in PV requires auditability, explainability, and human-in-the-loop for critical decisions. FDA E2B(R3) electronic submission deadline: April 1, 2026. |
| **Scale**               | Must handle 2,000–50,000+ cases/month depending on portfolio size. Must absorb 3–5x volume spikes during safety events without degradation. |

---

## Scope Boundaries

### In Scope

- Automated intake and triage of adverse event reports from structured and unstructured sources
- AI-assisted MedDRA and WHO Drug Dictionary coding
- Automated duplicate detection across the case database
- AI-generated clinical narratives with human review
- Touchless processing pipeline for routine non-serious cases
- Integration with one major safety database (Oracle Argus, Veeva Vault Safety, or LifeSphere)
- Regulatory submission formatting (ICH E2B(R3))
- Human-in-the-loop workflows for serious cases and causality override

### Out of Scope

- Safety signal detection and evaluation (separate analytical function)
- Benefit-risk assessment and regulatory decision-making
- Clinical trial safety reporting (separate SUSAR workflow)
- Social media and web scraping for AE detection (upstream data acquisition)
- Replacement of the safety database platform itself
- Regulatory authority interaction and query response handling
